#Canada #Vancouver #cancer therapy #Bold Therapeutics #BOLD-100

Bold Therapeutics Achieves Enrollment Midpoint in BOLD-100 Trial

Bold Therapeutics, a pioneering clinical-stage biopharmaceutical company, has announced a crucial milestone in its ongoing Phase 2 clinical trial for BOLD-100, a groundbreaking treatment aimed at metastatic colorectal cancer (mCRC). On October 15, 2026, the company revealed that it has successfully enrolled 60 patients in Arm VII of the BOLD-100-001 trial, which is evaluating the efficacy of BOLD-100 alongside standard FOLFOX chemotherapy.

The Trial Overview

This arm of the trial is a randomized, controlled study that compares two different dosages of BOLD-100: 500 mg/m² and 625 mg/m², both administered in conjunction with the established FOLFOX standard of care. The trial's primary objectives are to assess the drug's effectiveness, safety, and overall tolerability among participants. With the completion of the enrollment of 60 patients, which is half of the total targeted enrollment of 120, the company is now poised to conduct a pre-specified interim analysis. Results from this analysis are expected before the conclusion of 2026.

Global Patient Enrollment

Bold Therapeutics is actively recruiting participants across more than 25 clinical sites worldwide, including locations in Canada, South Korea, Germany, Italy, Spain, and the UK. This diverse enrollment strategy aims to include a wide patient demographic, ultimately supporting the clinical development of BOLD-100 in a segment of colorectal cancer treatment that faces substantial unmet medical needs.

Insights from Medical Experts

Dr. Grainne O'Kane, a Professor of Medical Oncology at St. Vincent's University Hospital in Dublin, expresses optimism regarding this advancement: "Second-line metastatic colorectal cancer remains a difficult-to-treat disease. Patients who progress after first-line treatment need access to innovative therapies like BOLD-100 as outcomes in this context remain poor." The achievement of reaching the trial's midpoint is seen as a vital step in understanding BOLD-100's performance alongside conventional chemotherapy treatments.

Company Leadership's Commitment

Glenn Walthall, the Chairman and Interim CEO of Bold Therapeutics, echoed these sentiments, highlighting the collective effort of employees, investigators, site teams, and the patients involved in the trial. "This milestone reflects the commitment of all those involved in the study," he stated, underscoring the importance of collaborative endeavors in clinical research.

Upcoming Presentation and Future Plans

In another key development, Bold Therapeutics will attend the upcoming BIO-Europe 2026 conference in Cologne, Germany, scheduled for November 9-11. During this event, the company is set to engage with current and potential collaborators, and it plans to present interim data from Arm VII at partnering meetings. This strategic exposure aims to bolster relationships with potential partners in advancing its clinical objectives.

About Bold Therapeutics and BOLD-100

Established in Vancouver, British Columbia, Bold Therapeutics is dedicated to the development of innovative metallotherapeutic agents designed to tackle hard-to-treat cancers, specifically gastrointestinal types. BOLD-100, which is derived from ruthenium, is designed to target the GRP78 protein—essential for cancer cell survival under stress. By increasing reactive oxygen species within tumor cells, BOLD-100 aims to induce DNA damage leading to cancer cell death. With its Phase 2 trial underway, BOLD-100 represents hope for improved treatment options in the face of challenging cancer diagnoses.

Looking Ahead

As the trial progresses, the interim results could significantly influence the future trajectory of BOLD-100 and its potential application in clinical practice, especially for patients dealing with the dire impacts of metastatic colorectal cancer. Bold Therapeutics remains committed to pushing the boundaries of cancer treatment innovation, fostering hope for both patients and their families worldwide.